Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers
Phase 1/2 Study of IMC-F106C in Advance PRAME-Positive Cancers
Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp in adult participants who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.
The IMC-F106C-101 Phase 1/2 study will be evaluated in patients with metastatic/unresectable tumors which include select Advanced Solid Tumors and will be conducted in two phases.
Inclusion Criteria:
Exclusion Criteria:
Hackensack, New Jersey 07601, United States
Oklahoma City, Oklahoma 73104, United States
Philadelphia, Pennsylvania 19104, United States
Wollstonecraft, New South Wales 2065, Australia
Rome, Roma 00168, Italy
Seriate, Roma 00168, Italy
Warsaw, 02-781, Poland
Pamplona, Navarre 31008, Spain